EVR 6.75MSFT 0.71DAL 0.73JPM 10.04ATD.TO 0.76MTD 11.7401CRWD -28.52
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.69
+0.35 (1.38%)
as of Jun 4, 2026, 8:00:00 pm Market Open.
579 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 4, 2026, 12:00 am

This summary was created by AI, based on 31 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges stemming from a patent cliff, leading to concerns about its drug pipeline and growth prospects in the coming years. Analysts emphasize the company's attractive dividend yield, which hovers around 6-7%, making it appealing for income-focused investors. However, many reviews suggest that the lack of earnings momentum and the need for new blockbuster drugs remain critical issues. Despite a robust pipeline and recent acquisitions, the absence of immediate catalysts for growth has left investors cautious. Overall, while Pfizer provides a decent dividend, its future performance hinges on successful drug development and navigating market sentiment around healthcare reforms.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY

Pfizer Inc(PFE)

Oct 27, 2004
Pharmaceuticals are cheaper than he has ever seen them. Cheap. Trading at low multiples.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$29.04

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 26, 2004
30% discount between their model price and current stock price.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$28.33

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 22, 2004
Has been beaten up. Has all the good things going for it according to analysts. Strong cash flow.
Photo of Robert StovallRobert Stovall
Owned
Unlock Rating
$27.74

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 20, 2004
Has had a very disappointing performance. Big pharmas have some issues facing them with regards to generic drugs. An extremely good company. Ran into problems because of their recall of Vioxx.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$28.30

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 12, 2004
Has dropped in sympathy with Merk and their recall of Vioxx as they have a similar product which is a big seller. Pharmaceutical industry as a whole has been hurt by generics and lagging R&D. Could drop further. All money is made in the US.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$29.86

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 07, 2004
Thinks its been oversold. Big pharmas have been in the dog house for at least 5 years.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$29.99

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 01, 2004
Interested in companies that have very good earnings growth and visibility. Have a pipeline that is not being valued appropriately.
Photo of Mary FarrellMary Farrell
Owned
Unlock Rating
$30.97

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 24, 2004
Best value in the market is in quality names. Best pharmaceutical company in the world. Just hasn't gone anywhere. New products are going into the pipeline.
Photo of Nicholas SargenNicholas Sargen
Owned
Unlock Rating
$29.66

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Sep 13, 2004
(A Top Pick Dec 29/03. Down 9%.) Have bought more on the dips. Health care industry in the US has suffered for the last 2 years. Showing strong revenue growth.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$32.13

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 10, 2004
A lot of drug stocks have been under pressure. All of the US drug companies are in a favorable position of having reasonable growth prospects.
Photo of Ray SteeleRay Steele
No
Unlock Rating
$31.86

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 08, 2004
Feels the US drug companies will continue to have tough sledding because of generics. This company is better equipped to fight that. Growth through acquisition.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$32.77

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 03, 2004
Best U.S. drug company. They have new products that were just introduced. Own Lipridor, the largest drug.
Photo of Jackee PrattJackee Pratt
Owned
Unlock Rating
$32.55

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
TRADE

Pfizer Inc(PFE)

Aug 30, 2004
Long-term: it is a good investment.
Photo of John ZechnerJohn ZechnerUnlock Rating
$32.46

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 25, 2004
A lot of the US drug stocks got ahead of themselves for the last couple of years. Actually looks pretty good now. At about 20X earnings now.
Photo of Bruce Campbell (1)Bruce Campbell (1)
No
Unlock Rating
$31.91

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 24, 2004
This is one of those stocks which everyone loves. This means everyone owns it, which concludes no one will buy any more. It is in a negative trend.
Photo of Ron MeiselsRon Meisels
No
Unlock Rating
$31.53

Stock price when the opinion was issued

$25.69

As of Jun 04, 2026. Market Open.

biotechnologypharmaceutical
Showing 706 to 720 of 883 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

RY.TO 5.13$270.94
BHP -2.05$88.8
TA.TO -2.08$18
V 7.78$320.18
TOU.TO -0.12$65.42

Today's Top Picks

EVR 6.75$346.84
MSFT 0.71$428.05
DAL 0.73$79.51
JPM 10.04$310.89
ATD.TO 0.76$80.79

Popular Articles

Latest Sell Signals

PRL.TO 0.07$21.2
CNQ.TO -0.14$66.22
SHOP.TO 4.46$161.54
RIO -2.455$105.405
BB.TO 0.3$14.4

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Joe Terranova

Virtus Investment Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica